摘要
５例急性白血病患者，行自体骨髓移植获得造血重建后，以白细胞介素Ⅱ（ＩＬ－２）合并应用同种异体ＬＡＫ细胞做为免疫疗法，以清除体内微小残留疾病，采用ＩＬ－２剂量为４×１０４ｕ／ｄ～２×１０５ｕ／ｄ。同种异体ＬＡＫ细胞来源于脐带血及胎儿胸腺、脾脏，初步结果表明，该方法安全，有效，毒副作用小，未见ＧＶＨＤ发生。
5 Patients with acute leukemia (2 ALL and 3 ANLL were treated with IL-2 and Allo-LAK cells after autologous bone marrow transplantation (ABMT). Human umbilical cord blood lymphocytes, fetal thymus or fetal spleen cells were used to prepare the Allo-LAK cells, which were induced by IL-2. It was found that the patients were tolerable to IL-2 at the dose of 4×104u～2 ×105u/day and to Allo-LAK cells. The major toxcities were fever and chills. Patients showed no sign of graft-versus host disease(GVHD). The preliminary results indicated that the infusion of low doses of IL-2 with Allo-LAK cells was safe and might be an effective approach in the treatment of patients with acute leukemia after ABMT.
